Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
NCT03896945 · Otsuka Pharmaceutical Development & Commercialization, Inc. · PHASE2/PHASE3 · terminated · last registry update 2026-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.” | – | Registry record, Otsuka Pharmaceutical Development & Commercialization, Inc. |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision